Capricor Therapeutics (CAPR) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 19.5% versus a gain of 8.0%. Over five years, CAPR leads with a +104.5% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($501.1 million vs $470.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | CBIO |
|---|---|---|
| Share price | $8.10 | $13.49 |
| Market cap | $470.93M | $501.11M |
| 1-day change | +4.52% | -0.59% |
| YTD return | -71.93% | +13.74% |
| 1-year return | +8.00% | +19.49% |
| 5-year return | +104.55% | -93.19% |
| EPS (TTM) | $-2.56 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $27.41 |
| 52-week low | $2.96 | $8.72 |
| Distance from 52-week high | -79.94% | -50.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +233.33% | +133.51% |
| Average volume | 6.83M | 387.23K |
| Shares outstanding | 58.14M | 37.14M |
| Employees | 231 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed CAPR by 11.5 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Healthcare · Biotechnology · 231 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Healthcare · Biotechnology · 69 employees
CAPR vs CBIO FAQ
Which is bigger, Capricor Therapeutics or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $501.11M compared with $470.93M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or CBIO?
CBIO returned +19.49% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.